Emerging Concepts in Clinical Nanomedicine: Modulation of Innate Immunity and Extracellular Vesicles

Emerging Concepts in Clinical Nanomedicine: Modulation of Innate Immunity and Extracellular Vesicles

January 4, 2019

Address

727 E. Tyler St.
Tempe, AZ 85281

Location

Biodesign Institute, Auditorium

Date and Time

January 22, 2019, 2:00 pm (Length: 1 hour 0 minutes)

iCal Download

Joy Wolfram, PhD, Wolfram Laboratory for Nanomedicine and Extracellular Vesicles, Department of Physiology and Biomedical Engineering, Department of Transplantation Medicine, Mayo Clinic Florida

Patients are dying every second! We need new and innovative solutions to treat diseases. As the director of the Nanomedicine and Extracellular Vesicles Laboratory at Mayo Clinic Florida, my goal is to develop innovative nanomedicines that bring the next generation of cancer and regenerative treatments directly to the clinic. We have designed several preclinical nanomedicine treatment strategies, some of which are expected to enter early stage clinical trials in the upcoming years. Examples of the therapeutic strategies we use include optimization of nanoparticle size and shape, temporarily blocking the liver to prevent nanoparticle clearance by this organ, and using patient-derived biological nanoparticles as drug carriers.

A major focus of my laboratory is development of extracellular vesicle therapeutics for cancer and regenerative medicine. Extracellular vesicles are endogenous nanoparticles that are secreted by all cells and play a pivotal role in cell communication both over short and long distances. Extracellular vesicles can be used for organotropic dug delivery and tissue regeneration as they contain a broad range of biologically active molecules, including lipids, nucleic acids, carbohydrates, and proteins. Site-specific delivery can be further improved by priming the mononuclear phagocyte system with pharmacological agents to reduce nanoparticle clearance by macrophages. Notably, systemically injected nanoparticles accumulate preferentially in tissue-resident macrophages of the liver and spleen, thereby limiting site-specific delivery. In fact, drug-repurposing strategies, such as the use of chloroquine, are promising for modulating macrophage activity to obtain reduced nanoparticle endocytosis.